Core Insights - Cidara Therapeutics has announced the promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to Senior Vice President of Clinical Development, effective May 1, 2025, during a critical phase of their influenza antiviral candidate CD388's development [1][2] Company Developments - The promotions are significant as Cidara advances its influenza antiviral candidate CD388 through the Phase 2b NAVIGATE trial and prepares for Phase 3 [2] - Dr. Davarpanah has over a decade of clinical development experience, previously holding leadership roles at Genentech/Roche, where she was responsible for early-stage molecules' advancement through clinical development and FDA approval [2][3] - Ms. Pavetto brings over 25 years of experience in clinical research and regulatory affairs, with a focus on infectious diseases, and has previously supported influenza antiviral and vaccine development at BARDA [4] Product Pipeline - Cidara's lead drug-Fc conjugate candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [5] - CD388 received Fast Track Designation from the FDA in June 2023, and the company completed enrollment of its 5,000 patient Phase 2b NAVIGATE trial in December 2024 [5]

Group 1: Company Overview - Cidara Therapeutics (CDTX) currently has a Momentum Style Score of B, indicating a positive momentum outlook [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] Group 2: Performance Metrics - CDTX shares have increased by 10.8% over the past week, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 6.19% [5] - Over the past month, CDTX's price change is 11.63%, compared to the industry's 2.23% [5] - In the last quarter, CDTX shares increased by 5.39%, and over the past year, they have gained 76.29%, while the S&P 500 has moved -7.64% and 10.16% respectively [6] Group 3: Trading Volume - The average 20-day trading volume for CDTX is 162,652 shares, which serves as a bullish indicator when combined with rising stock prices [7] Group 4: Earnings Outlook - In the past two months, one earnings estimate for CDTX has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$14.39 to -$7.12 [9] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [9] Group 5: Conclusion - Considering all performance metrics and earnings outlook, CDTX is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [11]

Core Insights - Cidara Therapeutics will participate in The Citizens Life Sciences Conference on May 7, 2025, at 11:00 AM ET, with a presentation format and a webcast available [1] - The company will also engage in one-on-one investor meetings during the event [2] Company Overview - Cidara Therapeutics is focused on developing drug-Fc conjugates (DFCs) using its proprietary Cloudbreak platform, which combines targeted small molecules or peptides with a human antibody fragment [3] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose and has received Fast Track Designation from the FDA [3] - CD388 completed Phase 2b enrollment in December 2024, and the company has also developed additional DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received IND clearance in July 2024 [3]

Core Insights - Cidara Therapeutics will report its Q1 2025 financial results and operational highlights on May 8, 2025, after U.S. market close [1] - A conference call and webcast will be held at 5:00 PM Eastern Time to discuss the results and business updates [2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies, including its lead candidate CD388, aimed at universal prevention of influenza [3] - CD388 received Fast Track Designation from the FDA in June 2023 and completed Phase 2b enrollment in December 2024 [3] - The company has also developed additional DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received IND clearance in July 2024 [3]

Core Insights - Phathom Pharmaceuticals has appointed Ted Schroeder to its Board of Directors, which is seen as a strategic move during a critical time for the company [1][3]. Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing novel treatments for gastrointestinal diseases, including the first-in-class potassium-competitive acid blocker (PCAB) vonoprazan, marketed as VOQUEZNA® [7]. Leadership Experience - Ted Schroeder brings over 30 years of experience in the biopharmaceutical industry, having held leadership roles in various companies and successfully guiding them through significant milestones and transactions [2][4]. - His previous roles include CEO of Nabriva Therapeutics and co-founder of Cadence Pharmaceuticals, which was acquired for $1.4 billion [4]. Strategic Importance - The appointment of Schroeder is expected to enhance Phathom's operational and commercial capabilities, particularly as the company aims to accelerate its commercial momentum and deliver innovative therapies to patients [3][5].

Company Overview - Cidara Therapeutics is a biotechnology company utilizing its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies [3] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [3] - Cidara is headquartered in San Diego, California [3] Recent Developments - Cidara will participate in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, at 11:00 AM ET [1] - The company has completed enrollment of its 5000 patient Phase 2b NAVIGATE trial for CD388 in December 2024 [3] - Cidara received Fast Track Designation from the U.S. FDA for CD388 in June 2023 [3] - In July 2024, Cidara received IND clearance for CBO421, targeting CD73 in solid tumors [3] Investor Engagement - Cidara will engage in one-on-one investor meetings during the Needham conference [2] - Investors interested in meetings should contact their Needham representative directly [2]

Summary of Cidara Therapeutics (CDTX) Core Viewpoint - Cidara Therapeutics (CDTX) shows potential for significant upside, with a mean price target of $38 indicating a 64.5% increase from the current price of $23.10 [1]. Price Target Analysis - The average price target consists of six estimates ranging from $33 to $46, with a standard deviation of $5.87, suggesting a consensus among analysts [2]. - The lowest estimate indicates a 42.9% increase, while the highest suggests a 99.1% upside [2]. - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [7]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [9]. - The Zacks Consensus Estimate for the current year has risen by 50.5% over the past month, with no negative revisions [10]. - CDTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11]. Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, and reliance solely on them may not yield favorable returns [5][8]. - Analysts may set optimistic price targets due to business incentives, which can inflate expectations [6].

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the "Other pharmaceuticals as preventive tools" panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled "What research is important to prepare and respond to H5N1 influenza outbreaks," will be held virtuall ...

SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara's presentations will highlight the study design, demographic information, and preliminary safety data from the ongoin ...

SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara’s presentations will highlight the study design, demographic information, and preliminary safety data from the ongoi ...